Sanofi Sunrise Co. MyoKardia Sets Heart On Untapped Cardiomyopathy Market
Emerging Company Profile: MyoKardia, a company backed by Sanofi's Sunrise initiative, has big development plans for the first therapeutic treatment targeting the root cause of hypertrophic cardiomyopathy – a chronic, progressive form of heart failure.
You may also be interested in...
Biotech hopes to accelerate clinical development plans for mavacamten after study meets several endpoints in obstructive hypertrophic cardiomyopathy, an unmet medical need.
The stereotypical view of an Alzheimer’s patient as an elderly person needs to change and interventions made earlier in the disease course, while we wait for novel drug therapies, said experts at a recent virtual meeting.
A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the novel coronavirus pandemic. While Biopharma companies secured more than $7.5bn in private financings between January and June.